ElmediX

ElmediX NV, founded in 2015, is a spin-off from the University of Antwerp in Belgium. It aims to develop disruptive solutions for pancreatic cancer and other metastatic cancers. The company has seven patent families protecting ElmediX technology and has established a strong intellectual property position globally (EU, US, China, and Hong Kong). The company also owns trademarks in these regions.